Joshua Pinto, Chief Financial Officer at Neumora Therapeutics, Inc. (NMRA), sold 168,614 shares at $11.78 ($2.0M) on 2024-08-26, disclosed to the SEC on 2024-08-26.
Scheduled sale ($2.0M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $11.63 | 28,496 | $331K | 16.8% |
| 2 | $11.63 | 28,496 | $331K | 16.8% |
| 3 | $11.59 | 24,169 | $280K | 14.2% |
| 4 | $11.59 | 24,169 | $280K | 14.2% |
| 5 | $11.78 | 31,642 | $373K | 18.9% |
| 6 | $11.78 | 31,642 |
| $373K |
| 18.9% |
| Total | $11.67 avg | 168,614 | $2.0M | 100% |
| Filing → |
| NMRA | SELL | 2024-08-27 | $357K | — | Filing → |